Conamax™(CMAX™): Faster, Cheaper, and Better Monoclonal Antibody Production.

Conagen is enabling biologics developers to rapidly produce high-quality therapeutic antibodies with humanized glycosylation patterns at a low cost. See how our proprietary microbial platform, Conamax, is replacing costly, fickle mammalian expression systems and making antibodies accessible to global patient populations.
Accelerate Your Antibody Pipeline

Conamax™: Faster, Cheaper, and Better Monoclonal Antibody Production.

Conagen is enabling biologics developers to rapidly produce high-quality therapeutic antibodies with humanized glycosylation patterns at a low cost. See how our proprietary microbial platform, Conamax, is replacing costly, fickle mammalian expression systems and making antibodies accessible to global patient populations.
Accelerate Your Antibody Pipeline

How Do We Make Life-Changing Therapeutics More Accessible?

Therapeutic monoclonal antibodies have changed the way we treat so many diseases, including cancer, autoimmune diseases, and rare disorders with high unmet need. Their clinical success has ramped up discovery activities and many biopharmaceutical pipelines hold incredible potential for improving patient outcomes.

But the high cost of monoclonal antibody production makes these blockbuster drugs expensive, limiting access to large patient populations in developing and industrialized countries. The reason for high production costs is, in part, due to the use of mammalian expression systems for antibody manufacturing. While these platforms enable human-like glycosylation, which is necessary for the stability and function of antibodies, there are many disadvantages to their widespread use: Cell growth and antibody expression require expensive serum, equipment, and downstream quality control. In addition, glycosylation patterns are sensitive to mild perturbations in culturing conditions, which can reduce the quality and yield of antibody production.

To solve these problems, we’ve developed Conamax, a robust, rapid, and inexpensive microbial antibody production platform for antibody developers and the global patient populations they serve.

Solving the High cost of monoclonal antibody production.

The high cost of monoclonal antibody production makes these blockbuster drugs expensive, limiting access to large patient populations in developing and industrialized countries. The reason for high production costs is, in part, due to the use of mammalian expression systems for antibody manufacturing. While these platforms enable human-like glycosylation, which is necessary for the stability and function of antibodies, there are many disadvantages to their widespread use: Cell growth and antibody expression require expensive serum, equipment, and downstream quality control. In addition, glycosylation patterns are sensitive to mild perturbations in culturing conditions, which can reduce the quality and yield of antibody production.

To solve these problems, we’ve developed Conamax, a robust, rapid, and inexpensive microbial antibody production platform for antibody developers and the global patient populations they serve.

The Advantages of Conamax for Production of Therapeutic Antibodies.

With rapid growth, human-like glyco-structures, and the application of large-scale fermentation bioprocesses, Conamax holds several advantages over the use of Chinese Hamster Ovary (CHO) cell lines, other mammalian expression systems, and yeast-based platforms.

Save Time With a Reliable, Scalable Platform, Proven in the Food Industry.

Our proprietary platform uses a marine protist with a rich and proven commercial history in the food industry. It is robustly fermentable and capable of rapid, reliable growth at scales up to 250,000 liters. Closely related organisms have been used for pre-clinical efficacy testing of other biologics and the Conamax platform has successfully produced several market-leading monoclonal antibodies and an antibody-drug conjugate, currently being developed.

Engineered for Human-Like Glycosylation, With no Fitness Defects.

Conamax has been genetically engineered to produce human-like glyco-structures and can also mimic the same glycosylation patterns found in antibodies produced in CHO cells. These genetic changes are well-tolerated, with no reductions in antibody yield or fitness defects. Our platform also circumvents the hyper-glycosylation and immunogenicity issues found in yeast-based antibody production systems and can be applied to a broad range of glycoproteins.

Low-Cost Bioproduction of Superior Antibodies.

The growth conditions and media required for Conamax are much simpler than those required for mammalian expression platforms, making for more economical antibody production. Simplified culturing greatly reduces the cost of downstream purification and quality control procedures and ultimately results in high-quality antibody production at productivities of greater than 1 gram/Liter/day.

We Can Help You Produce Better Biopharmaceuticals.

Let’s Partner.

Find out how Conamax™, (CMAX™), can transform your antibody discovery, development, and large-scale manufacturing.

Let’s Partner.

Find out how Conamax™, formerly CMAX, can transform your antibody discovery, development, and large-scale manufacturing. 

Scroll up